An Open-label Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs BMS 986177 (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 25 Jul 2017 Status changed from recruiting to completed.
- 30 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
- 30 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.